Evidence map›Paper›PMID 32425985›Full record

ReviewFrontiers in genetics2020

Review: Understanding Rare Genetic Diseases in Low Resource Regions Like Jammu and Kashmir - India.

Arshia Angural, Akshi Spolia, Ankit Mahajan, Vijeshwar Verma, Ankush Sharma, Parvinder Kumar, Manoj Kumar Dhar, Kamal Kishore Pandita, Ekta Rai, Swarkar Sharma

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Human-based complexFrontiers in cell and developmental biology · 2025
    Review
  5. Review
  6. Characterization of patients treated at a rare disease referral service: a descriptive study, 2016-2021.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2024
    Article
  7. Article
  8. Review
  9. CRISPR-Based Tools for Fighting Rare Diseases.Life (Basel, Switzerland) · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Arshia AnguralHuman Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.
Akshi SpoliaHuman Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.
Ankit MahajanHuman Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.
Vijeshwar VermaBioinformatics Infrastructure Facility, School of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.
Ankush SharmaShri Mata Vaishno Devi Narayana Superspeciality Hospital, Katra, India.
Parvinder KumarInstitute of Human Genetics, University of Jammu, Jammu, India.
Manoj Kumar DharInstitute of Human Genetics, University of Jammu, Jammu, India.
Kamal Kishore PanditaShri Mata Vaishno Devi Narayana Superspeciality Hospital, Katra, India.
Ekta RaiHuman Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.
Swarkar SharmaHuman Genetics Research Group, School of Biotechnology, Shri Mata Vaishno Devi University, Katra, India.
Shri Mata Vaishno Devi University · INUniversity of Jammu · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare diseases (RDs) are the clinical conditions affecting a few percentage of individuals in a general population compared to other diseases. Limited clinical information and a lack of reliable epidemiological data make their timely diagnosis and therapeutic management difficult. Emerging Next-Generation DNA Sequencing technologies have enhanced our horizons on patho-physiological understanding of many of the RDs and ushered us into an era of diagnostic and therapeutic research related to this ignored health challenge. Unfortunately, relevant research is meager in developing countries which lack a reliable estimate of the exact burden of most of the RDs. India is to be considered as the "Pandora's Box of genetic disorders." Owing to its huge population heterogeneity and high inbreeding or endogamy rates, a higher burden of rare recessive genetic diseases is expected and supported by the literature findings that endogamy is highly detrimental to health as it enhances the degree of homozygosity of recessive alleles in the general population. The population of a low resource region Jammu and Kashmir (J&K) - India, is highly inbred. Some of its population groups variably practice consanguinity. In context with the region's typical geographical topography, highly inbred population structure and unique but heterogeneous gene pool, a huge burden of known and uncharacterized genetic disorders is expected. Unfortunately, many suspected cases of genetic disorders remain undiagnosed or misdiagnosed due to lack of appropriate clinical as well as diagnostic resources in the region, causing patients to face a huge psycho-socio-economic crisis and many a time suffer life-long with their ailment. In this review, the major challenges associated with RDs are highlighted in general and an account on the methods that can be adopted for conducting fruitful molecular genetic studies in genetically vulnerable and low resource regions is also provided, with an example of a region like J&K - India.

Indexed as

Bottom-up ApproachconsanguinityendogamyIndiaJammu and KashmirNext-Generation DNA Sequencingrare diseases

Identifiers

PMID32425985
PMCPMC7203485
OpenAlexW3022977568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.